Product Data Sheet



Bifikafusp alfa

Cat. No.:	HY-P99479	
CAS No.:	1957239-90-5	
Target:	Others	
Pathway:	Others	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
BIOLOGICAL ACTIVITY			
Description	Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity ^[1] .		
In Vivo	Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; Female NMRI nude mice with MiaPaca-A2 xenografts) has antitumor activity against established pancreatic cancer ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NMRI nude mice with MiaPaca-A2 xenografts ^[1]		
	Annat Model.		
	Dosage:	1.43 and 4.29 MIU/kg	
	Administration:	Intraperitoneal injection; daily; for 10 days	
	Result:	Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.	

REFERENCES

[1]. Wagner K, et, al. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008 Aug 1;14(15):4951-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA